On 18 Dec 2019, Synthorx, Inc. (NASDAQ: THOR) changed -0.03% to recent value of $67.93. The stock transacted 343505 shares during most recent day however it has an average volume of 253.84K shares. It spotted trading -0.18% off 52-week high price. On the other end, the stock has been noted 517.55% away from the low price over the last 52-weeks.
Synthorx, Inc. (THOR) recently stated financial results and provided a business update for the third quarter ended September 30, 2019.
For the third quarter ended September 30, 2019, Synthorx stated a net loss of $12.2M, contrast to a net loss of $22.3M for the comparable period in 2018. For the nine months ended September 30, 2019, the company stated a net loss of $35.4M, contrast to a net loss of $28.4M for the comparable period in 2018. Included in the net losses for the three and nine months ended September 30, 2018 were non-cash charges of $16.3M related to the increase in the fair value of outstanding preferred stock purchase rights during the periods. The purchase rights were fully exercised in November 2018 and there were no such charges in 2019.
Research and development (R&D) expenses for the third quarter ended September 30, 2019 were $10.2M, contrast to $4.7M for the same period in 2018. For the nine months ended September 30, 2019, R&D expenses were $30.2M, contrast to $9.8M for the same period in 2018. The increase in the company’s R&D expenses for the 2019 periods are primarily attributable to the advancement of its THOR-707 program and related activities, including costs to develop its clinical supply manufacturing capabilities and costs associated with its Phase 1/2 clinical trial. Further, the company has incurred additional costs for its THOR-809 program in 2019, as contrast to 2018, and has expanded its R&D team in 2019 to support the development efforts for THOR-707, THOR-809 and its other programs.
General and administrative (G&A) expenses for the third quarter ended September 30, 2019 were $3.0M, contrast to $1.3M for the same period in 2018. For nine months ended September 30, 2019, G&A expenses were $8.4M, contrast to $2.3M for the same period in 2018. The increase in G&A expenses was primarily attributable to increased personnel and related costs as the company expanded its G&A team to support operations, including additional non-cash stock-based compensation cost of $0.5M and $1.3M for the three and nine months ended September 30, 2019, as contrast to the same periods in 2018. Furthermore, the company incurred additional costs in 2019 that were not incurred during the same period in 2018 as Synthorx now operates as a public company, including additional insurance, legal and accounting fees.
As of September 30, 2019, Synthorx stated cash, cash equivalents and investment securities of $150.9M, contrast to $188.4M at December 31, 2018.
Its earnings per share (EPS) expected to touch remained -831.80% for this year. The company has 32.25M of outstanding shares and 29.78M shares were floated in the market. According to the most recent quarter its current ratio was 18.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of 88.09% from the mean of 20 days, 199.59% from mean of 50 days SMA and performed 274.50% from mean of 200 days price. Company’s performance for the week was 0.22%, 330.75% for month and YTD performance remained 290.85%.